Cerus Corp (CERS) 6.54 $CERS
Cerus Provides an Update on Adoption by Blood Centers of America Members for the INTERCEPT Blood System for Platelets and Plasma
BusinessWire - Mon Jul 11, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that blood center members representing 54% of the aggregate volume of platelets produced by Blood Centers of America (BCA) have executed participation agreements for adoption of the INTERCEPT Blood System.
CERS: 6.54 (+0.09)
CORRECTING and REPLACING Cerus to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on July 13, 2016
BusinessWire - Fri Jul 08, 12:39PM CDT
In the first paragraph, presentation time should read 1:00 PM ET (instead of 1:30 PM ET).
CERS: 6.54 (+0.09)
Noteworthy Friday Option Activity: CERS, PODD, JUNO
DividendChannel.com - Fri Jul 08, 10:31AM CDT
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cerus Corp. , where a total volume of 6,653 contracts has been traded thus far today, a contract volume which is representative of...
CERS: 6.54 (+0.09)
Cerus and CEI Announce Donation of INTERCEPT Blood System Kits to HEMORIO for Emergency Preparedness Ahead of the Summer Olympic Games in Rio de Janeiro
BusinessWire - Wed Jul 06, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) and its distribution partner CEI Group (Brazil) today announced a donation of INTERCEPT Blood System pathogen reduction kits for platelets and plasma to HEMORIO, a public hospital responsible for transfusion medicine and hematology care for the state of Rio de Janeiro and part of the State Health Department and coordinator of the State Blood Network. HEMORIO is also the designated emergency preparedness blood center in Rio de Janeiro for the Summer Olympic Games, and this donation is aimed at protecting HEMORIO's platelet and plasma transfusion needs for emergency preparedness during the Olympic Games.
CERS: 6.54 (+0.09)
Cerus to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on July 13, 2016
BusinessWire - Tue Jul 05, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that Kevin Green, Cerus' vice president, finance and chief financial officer, is scheduled to present a corporate update at the Cantor Fitzgerald Healthcare Conference at 1:30 PM ET on Wednesday, July 13, 2016.
CERS: 6.54 (+0.09)
Cerus Corporation, the Transfusion Service of the Swiss Red Cross, and the University Hospital of Basel Receive a Grant of 2 Million Swiss Francs From the Swiss Red Cross Humanitarian Foundation for Whole Blood Pathogen Inactivation for Africa
BusinessWire - Thu Jun 30, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS), announced today that the Swiss Red Cross Humanitarian Foundation has awarded a grant of 2 million Swiss Francs to Cerus, the University Hospital of Basel, and the Swiss Transfusion SRC to complete the necessary clinical studies to develop a whole blood pathogen inactivation system for use in Africa.
CERS: 6.54 (+0.09)
Why Investors Have These Biotech Stocks on Their Radar? - Cerus, Juno Therapeutics, Chiasma, and Sage Therapeutics
PR Newswire - Mon Jun 27, 6:35AM CDT
The Healthcare arena was one of the better-performing sectors on Friday, once again proving to be generally less sensitive to market downturns. This morning, Stock-Callers.com has noted four equities in the Biotech space for close examination: Cerus Corp. (NASDAQ: CERS), Juno Therapeutics Inc. (NASDAQ: JUNO), Chiasma Inc. (NASDAQ: CHMA), and Sage Therapeutics Inc. (NASDAQ: SAGE). Sign up today for your complimentary trade alerts at:
CERS: 6.54 (+0.09), SAGE: 34.46 (+0.49), JUNO: 27.99 (+0.18), CHMA: 2.88 (-0.10)
Cerus Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million to Advance Its INTERCEPT Red Blood Cell Program
BusinessWire - Sun Jun 19, 3:00PM CDT
Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, to support Cerus' clinical development program for pathogen reduction of red blood cell (RBC) components, including access to funding that could support various activities, including funding studies necessary to support an FDA submission and accelerate commercial scale up to facilitate potential adoption by U.S. blood centers.
CERS: 6.54 (+0.09)
Showpad Helps Cerus Corporation Share Vital Information During Zika Epidemic
PR Newswire Europe - Wed Jun 01, 1:30AM CDT
Showpad, the leading sales enablement platform that guides reps to results, today announced that its customer Cerus Corporation, a biomedical company focused in the field of blood transfusion safety, is using Showpad to help educate its blood center customers about ways to maintain the safety of the blood supply during a Zika epidemic. Cerus is able to leverage the Showpad platform quickly and efficiently to share vital medical information with its field sales organization.
CERS: 6.54 (+0.09)
How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 6.54 (+0.09), RDUS: 42.31 (+1.06), ARWR: 5.85 (+0.12), FPRX: 45.24 (+0.70)
Health Canada Approves INTERCEPT Blood System for Plasma
BusinessWire - Mon May 23, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) today announced that Health Canada has approved the INTERCEPT Blood System for plasma. The INTERCEPT Blood System for plasma is intended to be used for the ex vivo preparation of pathogen-reduced, whole blood derived or apheresis plasma in order to reduce the risk of transfusion-transmitted infection (TTI).
CERS: 6.54 (+0.09)
Cerus reports 1Q loss
Automated Insights - Tue May 03, 3:37PM CDT
CONCORD, Calif. (AP) _ Cerus Corp. (CERS) on Tuesday reported a loss of $16.9 million in its first quarter.
CERS: 6.54 (+0.09)
Cerus Corporation Reports First Quarter 2016 Results
BusinessWire - Tue May 03, 3:01PM CDT
Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2016.
CERS: 6.54 (+0.09)
Cerus Announces that the Walter Reed National Military Medical Center Has Entered Into Routine Use of the INTERCEPT Blood System
BusinessWire - Tue May 03, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS), a biomedical products company focused in the field of blood transfusion safety, announced today that the Walter Reed National Military Medical Center (Walter Reed), a component of the Armed Services Blood Program, has begun routine use of the INTERCEPT Blood System for apheresis platelets. Walter Reed transfuses approximately 1,000 apheresis platelet units annually.
CERS: 6.54 (+0.09)
Cerus to Release First Quarter 2016 Results on May 3, 2016
BusinessWire - Tue Apr 19, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that its first quarter results will be released on Tuesday, May 3, 2016, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 6.54 (+0.09)
The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 16, 1:18PM CDT
The Aedes aegypti mosquito has become public enemy No. 1. Image source: Centers for Disease Control and Prevention. The Zika virus has been around for decades, but its prevalence has exploded since 2014. The virus itself, which is spread by the...
CERS: 6.54 (+0.09), INO: 9.22 (+0.11), MRK: 59.63 (+0.28), NLNK: 11.71 (-0.08), XON: 26.95 (+0.23), GSK: 43.71 (+0.33), SNY: 41.52 (+0.67)
Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma
BusinessWire - Wed Mar 16, 7:30AM CDT
Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced U.S. Food and Drug Administration (FDA) approval of the INTERCEPT Blood System for treatment of platelets suspended in 100% plasma. This extended label claim further enhances compatibility with commonly used platelet collection methods.
CERS: 6.54 (+0.09)
Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA's Revised Guidance Document on Bacterial Safety Standards for Platelets
BusinessWire - Tue Mar 15, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that the U.S. Food and Drug Administration (FDA) has issued a revised draft guidance document titled "Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Draft Guidance for Industry." The document is intended to provide blood centers with recommendations for controlling the risk of bacterial contamination of platelets, and pathogen reduction technology is included as a recommended method to reduce the risk of transfusion-transmitted sepsis.
CERS: 6.54 (+0.09)
Covered Call Alerts For Kinder Morgan, Himax Technologies Inc, US Steel, Yahoo! and CERUS Corporation Released By InvestorsObserver
PR Newswire - Thu Mar 10, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for KMI, HIMX, X, YHOO and CERS.
CERS: 6.54 (+0.09), KMI: 19.28 (+0.74), YHOO: 37.99 (+0.25), HIMX: 8.47 (+0.44), X: 20.02 (+0.99)
Cerus Provides an Update on Adoption by Blood Centers of America Members for the INTERCEPT Blood System for Platelets and Plasma
BusinessWire - Mon Jul 11, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that blood center members representing 54% of the aggregate volume of platelets produced by Blood Centers of America (BCA) have executed participation agreements for adoption of the INTERCEPT Blood System.
CERS: 6.54 (+0.09)
CORRECTING and REPLACING Cerus to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on July 13, 2016
BusinessWire - Fri Jul 08, 12:39PM CDT
In the first paragraph, presentation time should read 1:00 PM ET (instead of 1:30 PM ET).
CERS: 6.54 (+0.09)
Noteworthy Friday Option Activity: CERS, PODD, JUNO
DividendChannel.com - Fri Jul 08, 10:31AM CDT
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cerus Corp. , where a total volume of 6,653 contracts has been traded thus far today, a contract volume which is representative of...
CERS: 6.54 (+0.09)
Cerus and CEI Announce Donation of INTERCEPT Blood System Kits to HEMORIO for Emergency Preparedness Ahead of the Summer Olympic Games in Rio de Janeiro
BusinessWire - Wed Jul 06, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) and its distribution partner CEI Group (Brazil) today announced a donation of INTERCEPT Blood System pathogen reduction kits for platelets and plasma to HEMORIO, a public hospital responsible for transfusion medicine and hematology care for the state of Rio de Janeiro and part of the State Health Department and coordinator of the State Blood Network. HEMORIO is also the designated emergency preparedness blood center in Rio de Janeiro for the Summer Olympic Games, and this donation is aimed at protecting HEMORIO's platelet and plasma transfusion needs for emergency preparedness during the Olympic Games.
CERS: 6.54 (+0.09)
Cerus to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on July 13, 2016
BusinessWire - Tue Jul 05, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that Kevin Green, Cerus' vice president, finance and chief financial officer, is scheduled to present a corporate update at the Cantor Fitzgerald Healthcare Conference at 1:30 PM ET on Wednesday, July 13, 2016.
CERS: 6.54 (+0.09)
Cerus Corporation, the Transfusion Service of the Swiss Red Cross, and the University Hospital of Basel Receive a Grant of 2 Million Swiss Francs From the Swiss Red Cross Humanitarian Foundation for Whole Blood Pathogen Inactivation for Africa
BusinessWire - Thu Jun 30, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS), announced today that the Swiss Red Cross Humanitarian Foundation has awarded a grant of 2 million Swiss Francs to Cerus, the University Hospital of Basel, and the Swiss Transfusion SRC to complete the necessary clinical studies to develop a whole blood pathogen inactivation system for use in Africa.
CERS: 6.54 (+0.09)
Why Investors Have These Biotech Stocks on Their Radar? - Cerus, Juno Therapeutics, Chiasma, and Sage Therapeutics
PR Newswire - Mon Jun 27, 6:35AM CDT
The Healthcare arena was one of the better-performing sectors on Friday, once again proving to be generally less sensitive to market downturns. This morning, Stock-Callers.com has noted four equities in the Biotech space for close examination: Cerus Corp. (NASDAQ: CERS), Juno Therapeutics Inc. (NASDAQ: JUNO), Chiasma Inc. (NASDAQ: CHMA), and Sage Therapeutics Inc. (NASDAQ: SAGE). Sign up today for your complimentary trade alerts at:
CERS: 6.54 (+0.09), SAGE: 34.46 (+0.49), JUNO: 27.99 (+0.18), CHMA: 2.88 (-0.10)
Cerus Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million to Advance Its INTERCEPT Red Blood Cell Program
BusinessWire - Sun Jun 19, 3:00PM CDT
Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, to support Cerus' clinical development program for pathogen reduction of red blood cell (RBC) components, including access to funding that could support various activities, including funding studies necessary to support an FDA submission and accelerate commercial scale up to facilitate potential adoption by U.S. blood centers.
CERS: 6.54 (+0.09)
Showpad Helps Cerus Corporation Share Vital Information During Zika Epidemic
PR Newswire Europe - Wed Jun 01, 1:30AM CDT
Showpad, the leading sales enablement platform that guides reps to results, today announced that its customer Cerus Corporation, a biomedical company focused in the field of blood transfusion safety, is using Showpad to help educate its blood center customers about ways to maintain the safety of the blood supply during a Zika epidemic. Cerus is able to leverage the Showpad platform quickly and efficiently to share vital medical information with its field sales organization.
CERS: 6.54 (+0.09)
How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 6.54 (+0.09), RDUS: 42.31 (+1.06), ARWR: 5.85 (+0.12), FPRX: 45.24 (+0.70)
Health Canada Approves INTERCEPT Blood System for Plasma
BusinessWire - Mon May 23, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) today announced that Health Canada has approved the INTERCEPT Blood System for plasma. The INTERCEPT Blood System for plasma is intended to be used for the ex vivo preparation of pathogen-reduced, whole blood derived or apheresis plasma in order to reduce the risk of transfusion-transmitted infection (TTI).
CERS: 6.54 (+0.09)
Cerus reports 1Q loss
Automated Insights - Tue May 03, 3:37PM CDT
CONCORD, Calif. (AP) _ Cerus Corp. (CERS) on Tuesday reported a loss of $16.9 million in its first quarter.
CERS: 6.54 (+0.09)
Cerus Corporation Reports First Quarter 2016 Results
BusinessWire - Tue May 03, 3:01PM CDT
Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2016.
CERS: 6.54 (+0.09)
Cerus Announces that the Walter Reed National Military Medical Center Has Entered Into Routine Use of the INTERCEPT Blood System
BusinessWire - Tue May 03, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS), a biomedical products company focused in the field of blood transfusion safety, announced today that the Walter Reed National Military Medical Center (Walter Reed), a component of the Armed Services Blood Program, has begun routine use of the INTERCEPT Blood System for apheresis platelets. Walter Reed transfuses approximately 1,000 apheresis platelet units annually.
CERS: 6.54 (+0.09)
Cerus to Release First Quarter 2016 Results on May 3, 2016
BusinessWire - Tue Apr 19, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that its first quarter results will be released on Tuesday, May 3, 2016, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 6.54 (+0.09)
The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 16, 1:18PM CDT
The Aedes aegypti mosquito has become public enemy No. 1. Image source: Centers for Disease Control and Prevention. The Zika virus has been around for decades, but its prevalence has exploded since 2014. The virus itself, which is spread by the...
CERS: 6.54 (+0.09), INO: 9.22 (+0.11), MRK: 59.63 (+0.28), NLNK: 11.71 (-0.08), XON: 26.95 (+0.23), GSK: 43.71 (+0.33), SNY: 41.52 (+0.67)
Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma
BusinessWire - Wed Mar 16, 7:30AM CDT
Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced U.S. Food and Drug Administration (FDA) approval of the INTERCEPT Blood System for treatment of platelets suspended in 100% plasma. This extended label claim further enhances compatibility with commonly used platelet collection methods.
CERS: 6.54 (+0.09)
Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA's Revised Guidance Document on Bacterial Safety Standards for Platelets
BusinessWire - Tue Mar 15, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that the U.S. Food and Drug Administration (FDA) has issued a revised draft guidance document titled "Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Draft Guidance for Industry." The document is intended to provide blood centers with recommendations for controlling the risk of bacterial contamination of platelets, and pathogen reduction technology is included as a recommended method to reduce the risk of transfusion-transmitted sepsis.
CERS: 6.54 (+0.09)
Covered Call Alerts For Kinder Morgan, Himax Technologies Inc, US Steel, Yahoo! and CERUS Corporation Released By InvestorsObserver
PR Newswire - Thu Mar 10, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for KMI, HIMX, X, YHOO and CERS.
CERS: 6.54 (+0.09), KMI: 19.28 (+0.74), YHOO: 37.99 (+0.25), HIMX: 8.47 (+0.44), X: 20.02 (+0.99)
